NCT06120972View on ClinicalTrials.gov

Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency

PHASE2WithdrawnINTERVENTIONAL

Timeline

Start Date

January 17, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2029

Conditions

Ovarian Cancer

Interventions

DRUG

Olaparib tablet

Lynparza, is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase, an enzyme involved in DNA repair.